NCT00097955 - Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria | Biotech Hunter

Enrollment

496

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions

Diabetic Nephropathy

Interventions

DRUG

aliskiren

Trial Locations (12)

Novartis Pharmaceuticals, East Hanover

Investigative Site, Québec

Investigative Site, Hillerød

Investigative Site, Paris

Investigative Centers

Investigative Site, Athens

Investigative Site, Rome

Investigative Site, Rotterdam

Investigative Site, Bucharest

Investigative Site, Moscow

Investigative Site, Madrid

Investigative Site, London